Cancer

PUBLISHER: 360iResearch | PRODUCT CODE: 1380084

PUBLISHER: 360iResearch | PRODUCT CODE: 1380084

Malignant Mesothelioma Market by Drug Type (Carboplatin, Cisplatin, Gemcitabine), Treatment Type (Chemotherapy, Immunotherapy, Targeted therapy), Route of Administration, Distribution - Global Forecast 2023-2030

PUBLISHED: October 16, 2023

PAGES: 197 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Malignant Mesothelioma Market is projected to reach USD 1,347.15 million by 2030 from USD 716.10 million in 2022, at a CAGR of 8.21% during the forecast period.

Global Malignant Mesothelioma Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 716.10 million
Estimated Year Value [2023]	USD 772.67 million
Forecast Year Value [2030]	USD 1,347.15 million
CAGR (%)	8.21%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Malignant Mesothelioma Market.

Based on Drug Type, market is studied across Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, and Vinorelbine. The Pemetrexed is projected to witness significant market share during forecast period.

Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, and Targeted therapy. The Chemotherapy is further studied across Local Chemotherapy and Systemic Chemotherapy. The Chemotherapy is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies. The Online Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Malignant Mesothelioma Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Malignant Mesothelioma Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Malignant Mesothelioma Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Advanz Pharma Corp., Argenx SE, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories, Eisai Co., Ltd., Eli Lilly and Company, Emcure Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Karyopharm Therapeutics Inc., Merck & Co., Inc., Mylan N.V., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Novocure GmbH, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Polaris Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Ltd., and Wellona Pharma.

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Malignant Mesothelioma Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Malignant Mesothelioma Market?

3. What is the competitive strategic window for identifying opportunities in the Malignant Mesothelioma Market?

4. What are the latest technology trends and regulatory frameworks in the Malignant Mesothelioma Market?

5. What is the market share of the leading vendors in the Malignant Mesothelioma Market?

6. Which modes and strategic moves are suitable for entering the Malignant Mesothelioma Market?

Product Code: MRR-C002B1C99591

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Malignant Mesothelioma Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidence of malignant mesothelioma worldwide
  - 5.1.1.2. Increase in the number of clinical trials for the treatment of malignant mesothelioma
  - 5.1.1.3. Use of diagnostic and prognostic biomarkers for malignant mesothelioma treatment
- 5.1.2. Restraints
  - 5.1.2.1. High cost of malignant mesothelioma surgical treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Introduction of novel therapies for the treatment of malignant mesothelioma
  - 5.1.3.2. Favorable funding landscape for research on malignant mesothelioma
- 5.1.4. Challenges
  - 5.1.4.1. Adverse effects associated with the treatment of malignant mesothelioma
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Malignant Mesothelioma Market, by Drug Type

6.1. Introduction
6.2. Carboplatin
6.3. Cisplatin
6.4. Gemcitabine
6.5. Pemetrexed
6.6. Vinorelbine

7. Malignant Mesothelioma Market, by Treatment Type

7.1. Introduction
7.2. Chemotherapy
- 7.3.1. Local Chemotherapy
- 7.3.2. Systemic Chemotherapy
7.3. Immunotherapy
7.4. Targeted therapy

8. Malignant Mesothelioma Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Malignant Mesothelioma Market, by Distribution

9.1. Introduction
9.2. Hospitals Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies

10. Americas Malignant Mesothelioma Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Malignant Mesothelioma Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Malignant Mesothelioma Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. AbbVie Inc.
- 14.1.2. Advanz Pharma Corp.
- 14.1.3. Argenx SE
- 14.1.4. AstraZeneca Plc
- 14.1.5. Boehringer Ingelheim GmbH
- 14.1.6. Bristol-Myers Squibb Company
- 14.1.7. Cipla Limited
- 14.1.8. Dr. Reddy's Laboratories
- 14.1.9. Eisai Co., Ltd.
- 14.1.10. Eli Lilly and Company
- 14.1.11. Emcure Pharmaceuticals Limited
- 14.1.12. F. Hoffmann-La Roche Ltd.
- 14.1.13. Fresenius Kabi AG
- 14.1.14. Karyopharm Therapeutics Inc.
- 14.1.15. Merck & Co., Inc.
- 14.1.16. Mylan N.V.
- 14.1.17. Nichi-Iko Pharmaceutical Co., Ltd.
- 14.1.18. Novartis AG
- 14.1.19. Novocure GmbH
- 14.1.20. Ono Pharmaceutical Co. Ltd.
- 14.1.21. Pfizer Inc.
- 14.1.22. Polaris Pharmaceuticals, Inc.
- 14.1.23. Sanofi S.A.
- 14.1.24. Sun Pharmaceuticals Industries Ltd.
- 14.1.25. Wellona Pharma
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing